NM-2201, alternatively recognized as CBL-2201, belongs to the family of indole-based synthetic cannabinoids. It is theorized to exhibit analogous characteristics to its closely related counterparts, 5F-PB-22 and NNE1. These compounds are categorized as full agonists, demonstrating an indiscriminate binding affinity to CB1 and CB2 receptors at a low nanomolar level.

IUPAC name
CAS Number2042201-16-9 
PubChem CID91864534
CompTox Dashboard (EPA)DTXSID201009986
Chemical and physical data
Molar mass375.443 g·mol−1


NM-2201 functions as a full agonist, displaying a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 receptors, as reported in reference. Its use has been associated with severe adverse effects in individuals, as documented in the connection.

Legal Status

NM-2201 is prohibited in Sweden, Germany (Anlage II), and Japan, as stated in the references, respectively. Additionally, it is subject to regulatory control in various other jurisdictions through analog laws.

On May 30, 2018, the United States Drug Enforcement Administration, under the Department of Justice, issued a notice of intent to categorize NM-2201 and four other synthetic cannabinoids under Schedule I of the Controlled Substances Act. This notice occurred on June 29, 2018, as detailed in reference.


NM-2201 was associated with an incident in December 2015, wherein 25-30 individuals in Ocala, FL, were hospitalized due to seizures.


1. What is NM-2201?

NM-2201 is a synthetic cannabinoid that belongs to a class of compounds designed to mimic the effects of natural cannabinoids found in cannabis.

2. What are the effects of NM-2201?

NM-2201 is reported to have effects similar to those of cannabis, including euphoria, relaxation, altered perception, and increased sociability. However, it can also cause adverse effects, including anxiety and hallucinations.

3. Is NM-2201 legal?

The legal status of NM-2201 varies by country and region. It is banned in several countries, such as Sweden, Germany, and Japan. In other places, it may be controlled under analog or synthetic drug laws.

4. Is NM-2201 safe to use?

NM-2201 has been linked to severe adverse events, including seizures. Its safety for human consumption is not well-established, and using synthetic cannabinoids can carry health risks. It is crucial to exercise caution and avoid its use.

5. How is NM-2201 typically consumed?

NM-2201 is commonly found as a powder, which can be dissolved in a liquid or vaporized and inhaled. It is essential to be aware of the potential health risks associated with these consumption methods.

6. Is NM-2201 addictive?

Like other synthetic cannabinoids and cannabis, NM-2201 has the potential for dependence and addiction, especially with frequent and heavy use.

7. What should I do if I experience adverse effects from NM-2201?

If you or someone you know experiences adverse effects, such as anxiety, hallucinations, or seizures, seek immediate medical attention. It’s essential to be cautious and informed about the potential risks associated with synthetic cannabinoids.

8. Can NM-2201 be used for medical purposes?

NM-2201 is not approved for any medical purposes and is not considered a medication. It is primarily used recreationally and is often considered a designer drug.

9. Where can I find more information about NM-2201?

You can find more information about NM-2201 in scientific literature, law enforcement agencies, or drug regulation websites. However, always be cautious when seeking information about substances like NM-2201, and ensure that your sources are reputable and trustworthy.


  1. Kondrasenko AA, Goncharov EV, Dugaev KP, and Rubaylo AI. (December 2015). “CBL-2201: Unveiling a New Designer Drug – A Report on Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate”. Published in Forensic Science International, Volume 257, Pages 209–213. DOI: 10.1016/j.forsciint.2015.08.023. PMID: 26386336.
  2. Learn more about “NM-2201” from Cayman Chemical. Retrieved on 9 July 2015.
  3. Namera A, Kawamura M, Nakamoto A, Saito T, and Nagao M. (2015). “A Comprehensive Review of Detection Methods for Synthetic Cannabinoids and Cathinones”. Published in Forensic Toxicology, Volume 33, Issue 2, Pages 175–194. DOI: 10.1007/s11419-015-0270-0. PMC 4525208. PMID: 26257831.
  4. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Baranovsky A, and Shafran Y. (November 2014). “Synthetic Cannabinoids as Designer Drugs: New Members of the Indol-3-carboxylates and Indazole-3-carboxylates Series – Identification and Analytical Data”. Published in Forensic Science International, Volume 244, Pages 263–275. DOI: 10.1016/j.forsciint.2014.09.013. PMID: 25305529.
  5. Hess C, Schoeder CT, Pillaiyar T, Madea B, and Müller CE. (2016). “Pharmacological Evaluation of Synthetic Cannabinoids Identified in Spice”. Published in Forensic Toxicology, Volume 34, Issue 2, Pages 329–343. DOI: 10.1007/s11419-016-0320-2. PMC 4929166. PMID: 27429655.
  6. Samra K, Boon IS, Packer G, and Jacob S. (April 2017). “Insights into ‘Black Mamba’ – A Case Report”. Published in BMJ Case Reports, 2017, bcr–2016–218431. DOI: 10.1136/bcr-2016-218431. PMC 5534782. PMID: 28433979.
  7. “Cannabinoider föreslås bli klassade som hälsofarlig vara” (in Swedish). Retrieved from Folkhälsomyndigheten on 9 July 2015.
  8. “Gesetz über den Verkehr mit Betäubungsmitteln Anlage II” (in German). Retrieved from Bundesministerium der Justiz und für Verbraucherschutz on 24 October 2016.
  9. Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, and Huestis MA. (January 2017). “In vitro and in vivo Human Metabolism of the New Synthetic Cannabinoid NM-2201 (CBL-2201)”. Published in Forensic Toxicology, Volume 35, Issue 1, Pages 20–32. DOI: 10.1007/s11419-016-0326-9. PMC 5342258. PMID: 28286577.
  10. “2018 – Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA Into Schedule I”. Retrieved from www.deadiversion.usdoj.gov on 2018-06-15.

Leave a Comment

Your email address will not be published. Required fields are marked *